HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBI) (“ReGen”) announced today that the Orthopaedic and Rehabilitation Devices Advisory Panel (“Orthopaedic Panel”) of the Food and Drug Administration (“FDA”) met on Friday, November 14, 2008 to provide advice and recommendations regarding the ReGen collagen scaffold device in the context of its 510(k) submission. At the meeting, ReGen and FDA staff made presentations to the Orthopaedic Panel and members of the Orthopaedic Panel asked questions and deliberated on the presentations and other information. The Orthopaedic Panel discussed and commented on questions provided by the FDA. A summary of the panel meeting is available on the FDA website at http://www.fda.gov/cdrh/meetings/111408-summary.html.
